Get started
VERTEX PHARMACEUTICALSVERTEX PHARMACEUTICALSVERTEX PHARMACEUTICALS

VERTEX PHARMACEUTICALS

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

4VRTX chart


Full chart

4VRTX upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪112.66 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.00 EUR
Net income (FY)
‪−517.38 M‬ EUR
Revenue (FY)
‪10.61 B‬ EUR
Shares float
‪255.90 M‬
Beta (1Y)
1.23

Employees


Employees (FY)
‪6.1 K‬
Change (1Y)
+700 +12.96%
Revenue / Employee (1Y)
‪1.74 M‬ EUR
Net income / Employee (1Y)
‪−84.82 K‬ EUR

About Vertex Pharmaceuticals Incorporated


Sector
Health Technology
CEO
Reshma Kewalramani
Headquarters
Boston
Website
vrtx.com
Founded
1989
FIGI
BBG00KGFV1H9
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

4VRTX news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where 4VRTX is featured.

See all sparks 

Frequently Asked Questions


The current price of 4VRTX is 438.95 EUR — it has increased by 0.10% in the past 24 hours. Watch VERTEX PHARMACEUTICALS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EUROTLX exchange VERTEX PHARMACEUTICALS stocks are traded under the ticker 4VRTX.
4VRTX stock has fallen by −4.03% compared to the previous week, the month change is a 7.38% rise, over the last year VERTEX PHARMACEUTICALS has showed a 11.14% increase.
We've gathered analysts' opinions on VERTEX PHARMACEUTICALS future price: according to them, 4VRTX price has a max estimate of 592.42 EUR and a min estimate of 317.89 EUR. Watch 4VRTX chart and read a more detailed VERTEX PHARMACEUTICALS stock forecast: see what analysts think of VERTEX PHARMACEUTICALS and suggest that you do with its stocks.
4VRTX reached its all-time high on Nov 5, 2024 with the price of 487.60 EUR, and its all-time low was 117.05 EUR and was reached on Dec 6, 2017. View more price dynamics on 4VRTX chart.
See other stocks reaching their highest and lowest prices.
4VRTX stock is 0.10% volatile and has beta coefficient of 1.23. Track VERTEX PHARMACEUTICALS stock price on the chart and check out the list of the most volatile stocks — is VERTEX PHARMACEUTICALS there?
Today VERTEX PHARMACEUTICALS has the market capitalization of ‪112.66 B‬, it has decreased by −6.44% over the last week.
Yes, you can track VERTEX PHARMACEUTICALS financials in yearly and quarterly reports right on TradingView.
VERTEX PHARMACEUTICALS is going to release the next earnings report on Apr 30, 2025. Keep track of upcoming events with our Earnings Calendar.
4VRTX earnings for the last quarter are 3.84 EUR per share, whereas the estimation was 3.88 EUR resulting in a −0.90% surprise. The estimated earnings for the next quarter are 4.06 EUR per share. See more details about VERTEX PHARMACEUTICALS earnings.
VERTEX PHARMACEUTICALS revenue for the last quarter amounts to ‪2.81 B‬ EUR, despite the estimated figure of ‪2.69 B‬ EUR. In the next quarter, revenue is expected to reach ‪2.73 B‬ EUR.
4VRTX net income for the last quarter is ‪881.94 M‬ EUR, while the quarter before that showed ‪938.92 M‬ EUR of net income which accounts for −6.07% change. Track more VERTEX PHARMACEUTICALS financial stats to get the full picture.
No, 4VRTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 16, 2025, the company has ‪6.10 K‬ employees. See our rating of the largest employees — is VERTEX PHARMACEUTICALS on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. VERTEX PHARMACEUTICALS EBITDA is ‪23.38 M‬ EUR, and current EBITDA margin is 41.56%. See more stats in VERTEX PHARMACEUTICALS financial statements.
Like other stocks, 4VRTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade VERTEX PHARMACEUTICALS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So VERTEX PHARMACEUTICALS technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating VERTEX PHARMACEUTICALS stock shows the buy signal. See more of VERTEX PHARMACEUTICALS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.